1. Home
  2. FBYD vs AGEN Comparison

FBYD vs AGEN Comparison

Compare FBYD & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Falcon's Beyond Global Inc.

FBYD

Falcon's Beyond Global Inc.

HOLD

Current Price

$8.26

Market Cap

360.1M

Sector

N/A

ML Signal

HOLD

Logo Agenus Inc.

AGEN

Agenus Inc.

BUY

Current Price

$6.16

Market Cap

335.6M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
FBYD
AGEN
Founded
2021
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
360.1M
335.6M
IPO Year
2023
1999

Fundamental Metrics

Financial Performance
Metric
FBYD
AGEN
Price
$8.26
$6.16
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $26.33
AVG Volume (30 Days)
70.7K
★ 1.0M
Earning Date
11-13-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 100.00
EPS
0.04
★ 0.96
Revenue
$14,896,000.00
★ $42,877,086.00
Revenue This Year
N/A
$9.64
Revenue Next Year
N/A
N/A
P/E Ratio
$208.50
★ $6.29
Revenue Growth
★ 120.85
89.95
52 Week Low
$3.71
$2.71
52 Week High
$29.02
$10.19

Technical Indicators

Market Signals
Indicator
FBYD
AGEN
Relative Strength Index (RSI) 48.70 35.80
Support Level $6.01 $2.96
Resistance Level $8.65 $8.64
Average True Range (ATR) 0.52 0.59
MACD 0.05 -0.28
Stochastic Oscillator 22.45 4.18

Price Performance

Historical Comparison
FBYD
AGEN

About FBYD Falcon's Beyond Global Inc.

Falcons Beyond Global Inc is a visionary entertainment and technology enterprise. The group designs, develops, engineers, delivers, and commercializes immersive physical and digital experiences for brands, developers, and destination operators world-wide, as well as for its own portfolio of entertainment and technology concepts. The Company has five operating segments: Falcon's Creative Group, Destinations Operations, PDP, Falcon's Beyond Brands, and Falcon's Attractions. It earns the majority of the revenue from Falcon's Creative Group segment.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: